Teladoc Health, Inc.
TDOCNYSEHealthcare● Active
$7.08
+$0.03(+0.43%)
Market Cap$1.3B
P/E Ratio—
52W High$9.77
52W Low$4.4
Teladoc Health, Inc. (TDOC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
TDOC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
-$0.36
Est. -$0.34 · -5.5%
Revenue
$0.61B
Est. $0.61B · +0.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▼ Miss EPS
TDOC reports quarterly as a NYSE-listed Medical - Healthcare Information Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | -$0.24 | — | — | — | $0.61B | — |
| ▼ Q2 FY2026 | Apr 29, 2026 | -$0.34 | -$0.36 | -5.5% | $0.61B | $0.61B | +0.5% |
| ▲ Q1 FY2026 | Feb 25, 2026 | -$0.19 | -$0.14 | +26.3% | $0.64B | $0.64B | +1.1% |
| ▲ Q4 FY2025 | Oct 29, 2025 | -$0.26 | -$0.21 | +19.2% | $0.63B | $0.64B | -1.4% |
| ▲ Q3 FY2025 | Jul 29, 2025 | -$0.27 | -$0.19 | +29.6% | $0.63B | $0.63B | +0.7% |
| ▲ Q2 FY2025 | Apr 30, 2025 | -$0.33 | -$0.19 | +42.4% | $0.63B | $0.62B | +1.6% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -$0.21 | -$0.28 | -33.3% | $0.64B | $0.64B | +0.2% |
| ▲ Q4 FY2024 | Oct 30, 2024 | -$0.29 | -$0.19 | +34.5% | $0.64B | $0.64B | +0.0% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
-$0.24
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Miss
EPS Actual
-$0.36
EPS Est.
-$0.34
EPS Surpr.
-5.5%
Revenue
$0.61B
Q1 FY2026
Feb 25, 2026Beat
EPS Actual
-$0.14
EPS Est.
-$0.19
EPS Surpr.
+26.3%
Revenue
$0.64B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.26
EPS Surpr.
+19.2%
Revenue
$0.63B
Q3 FY2025
Jul 29, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.27
EPS Surpr.
+29.6%
Revenue
$0.63B
Q2 FY2025
Apr 30, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.33
EPS Surpr.
+42.4%
Revenue
$0.63B
Q1 FY2025
Feb 26, 2025Miss
EPS Actual
-$0.28
EPS Est.
-$0.21
EPS Surpr.
-33.3%
Revenue
$0.64B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
-$0.19
EPS Est.
-$0.29
EPS Surpr.
+34.5%
Revenue
$0.64B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.08 | $-0.08 | $-0.08 | 3 |
| Q3 FY2028 | $-0.15 | $-0.14 | $-0.14 | 3 |
| Q2 FY2028 | $-0.21 | $-0.20 | $-0.20 | 3 |
| Q1 FY2028 | $-0.23 | $-0.22 | $-0.22 | 3 |
| Q4 FY2027 | $-0.11 | $-0.11 | $-0.11 | 2 |
| Q3 FY2027 | $-0.16 | $-0.15 | $-0.15 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.7B | $0.7B | $0.7B | 14 |
| Q3 FY2028 | $0.6B | $0.6B | $0.7B | 7 |
| Q2 FY2028 | $0.6B | $0.6B | $0.7B | 7 |
| Q1 FY2028 | $0.6B | $0.6B | $0.6B | 10 |
| Q4 FY2027 | $0.6B | $0.7B | $0.7B | 15 |
| Q3 FY2027 | $0.6B | $0.6B | $0.6B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 29, 2026 | -5.5% | $6.00 | $5.95 | -0.83% |
| ▲ Q1 FY2026 | Feb 25, 2026 | +26.3% | $4.54 | $4.65 | +2.42% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +19.2% | $8.36 | $8.23 | -1.56% |
| ▲ Q3 FY2025 | Jul 29, 2025 | +29.6% | $8.20 | $7.53 | -8.17% |
| ▲ Q2 FY2025 | Apr 30, 2025 | +42.4% | $7.33 | $7.19 | -1.91% |
| ▼ Q1 FY2025 | Feb 26, 2025 | -33.3% | $11.18 | $10.99 | -1.70% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +34.5% | $8.92 | $8.86 | -0.67% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +22.2% | $9.73 | $9.43 | -3.08% |
Q2 FY2026-0.83%
Report Date
Apr 29, 2026
EPS Beat/Miss
-5.5%
Price Before
$6.00
Price After
$5.95
Q1 FY2026+2.42%
Report Date
Feb 25, 2026
EPS Beat/Miss
+26.3%
Price Before
$4.54
Price After
$4.65
Q4 FY2025-1.56%
Report Date
Oct 29, 2025
EPS Beat/Miss
+19.2%
Price Before
$8.36
Price After
$8.23
Q3 FY2025-8.17%
Report Date
Jul 29, 2025
EPS Beat/Miss
+29.6%
Price Before
$8.20
Price After
$7.53
Q2 FY2025-1.91%
Report Date
Apr 30, 2025
EPS Beat/Miss
+42.4%
Price Before
$7.33
Price After
$7.19
Q1 FY2025-1.70%
Report Date
Feb 26, 2025
EPS Beat/Miss
-33.3%
Price Before
$11.18
Price After
$10.99
Q4 FY2024-0.67%
Report Date
Oct 30, 2024
EPS Beat/Miss
+34.5%
Price Before
$8.92
Price After
$8.86
Q3 FY2024-3.08%
Report Date
Jul 31, 2024
EPS Beat/Miss
+22.2%
Price Before
$9.73
Price After
$9.43
Avg Beat Reaction-2.16%
Avg Miss Reaction-1.26%
Beat Rate6 / 8 quarters
Largest Move-8.17% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: TDOC ends December
Teladoc Health, Inc. (TDOC) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $-0.36 — missing the analyst consensus of $-0.34 by -5.5%. The next TDOC earnings date is expected around September 1, 2026.
Each quarter, investors track TDOC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. TDOC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
TDOC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
TDOC earnings · 5 questionsTeladoc Health, Inc.'s next earnings report is expected around September 1, 2026. TDOC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; TDOC historically reports after market close (AMC).
TDOC earnings datewhen is TDOC earningsTDOC next earnings datewhen does TDOC report earningsTDOC earnings calendar
▸ Source: FMP · Teladoc Health, Inc. SEC filings · US GAAP · Teladoc Health, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026